{"id":5513,"date":"2019-07-26T15:39:09","date_gmt":"2019-07-26T13:39:09","guid":{"rendered":"https:\/\/capcs.md\/?p=5513"},"modified":"2019-08-01T12:00:13","modified_gmt":"2019-08-01T10:00:13","slug":"comunicat-de-presa","status":"publish","type":"post","link":"https:\/\/capcs.md\/en\/comunicat-de-presa\/","title":{"rendered":"Comunicat de pres\u0103 cu referire la procedura de achizi\u021bie a analogilor de insulin\u0103 \u0219i a preparatului Desmopressinum \u00een scopul realiz\u0103rii Programului Na\u021bional de profilaxie \u0219i combaterea diabetului zaharat \u0219i diabetului insipid pentru anul 2019"},"content":{"rendered":"<p style=\"text-align: center;\"><span style=\"color: #000000;\"><strong>Comunicat de pres\u0103<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Centrul pentru Achizi\u021bii Publice Centralizate \u00een S\u0103n\u0103tate a desf\u0103\u0219urat procedura de achizi\u021bie public\u0103 privind \u201d<em>Achizi\u021bionarea analogilor de insulin\u0103 \u0219i a preparatului Desmopressinum \u00een scopul realiz\u0103rii Programului Na\u021bional de profilaxie \u0219i combaterea diabetului zaharat \u0219i diabetului insipid pentru anul 2019<\/em>\u201d \u00een baza Hot\u0103r\u00e2rii Guvernului nr. 1128 din 2016 \u0219i a solicit\u0103rii Ministerului S\u0103n\u0103t\u0103\u021bii, Muncii \u0219i Protec\u021biei Sociale (MSMPS) din data de 24.08.2018.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Prin scrisoarea sa, MSMPS a indicat lista medicamentelor care urmau a fi achizi\u021bionate, inclusiv <strong><u>DCI &#8211; Insulinum glarginum cu DOZA &#8211; 100 UI\/ml 3 ml \u0219i FORMA FARMACEUTIC\u0102 &#8211; solu\u021bie injectabil\u0103 \u00een stilou injector preumplut,<\/u><\/strong> \u0219i suma estimativ\u0103 care constituie 22\u00a0016 128,00 lei.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Preciz\u0103m faptul c\u0103, la data de 16.11.2018 \u00een baza scrisorii MSMPS\u00a0 nr. 17\/3185 din 15.11.2018, a fost majorat\u0103 cantitatea analogilor de insulin\u0103 (inclusiv Insulinum glarginum) \u0219i a fost completat\u0103 lista de achizi\u021bii cu\u00a0 testele pentru m\u0103surarea nivelului de glicemie \u00een s\u00e2nge. Totodat\u0103, a fost ajustat bugetul alocat, \u0219i anume: de la 22 016 128,00 lei la 124 254 934,00 lei.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>La data de 28.09.2018, CAPCS a demarat licita\u021bia public\u0103 nr. 18\/03958, la care au fost acceptate doar medicamente autorizate \u00een RM &#8211; \u00eenregistrate \u00een Nomenclatorul de Stat al Medicamentelor din Republica Moldova.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>La data ini\u021bierii procedurii de achizi\u021bie, \u00een Nomenclatorul de Stat al Medicamentelor din Republica Moldova, cu DCI &#8211; Insulinum glarginum cu DOZA &#8211; 100 UI\/ml 3 ml \u0219i FORMA FARMACEUTIC\u0102 &#8211; solu\u021bie injectabil\u0103 \u00een stilou injector preumplut, era \u00eenregistrat <strong><u>doar un singur medicament<\/u><\/strong> ce nu asigura concuren\u021ba \u00een domeniul achizi\u021biilor publice \u0219i utilizarea eficient\u0103 a banilor publici conform art. 6 din Legea nr. 131 din 03.07.2015 privind achizi\u021biile publice.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Astfel, CAPCS a constatat c\u0103 \u00een <strong>Nomenclatorul de Stat al Medicamentelor din Republica Moldova<\/strong>, pentru DCI <strong>Insulinum glarginum<\/strong>, pe l\u00e2ng\u0103 FORMA FARMACEUTIC\u0102 &#8211; <strong><u>solu\u021bie injectabil\u0103 \u00een stilou injector preumplut<\/u><\/strong> este \u00eenregistrat\u0103 \u0219i FORMA FARMACEUTIC\u0102 &#8211; <strong><u>Solu\u021bie injectabil\u0103 \u00een cartu\u0219<\/u><\/strong>, diferen\u021ba const\u0103 doar \u00een ambalajul primar \u2013 stilou injector preumplut \u0219i cartu\u0219.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>La data de <strong><u>29.10.2018, <\/u><\/strong>\u00een Nomenclatorul de Stat al Medicamentelor din Republica Moldova, erau \u00eenregistrate medicamentele Lantus \u0219i Strim,\u00a0 respectiv erau considerate bioechivalente \u0219i similare, iar efectele lor, referitoare la eficacitate \u0219i siguran\u021b\u0103 &#8211; <strong><u>acelea\u0219i<\/u><\/strong>.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>\u00cen aceast\u0103 ordine de idei, au fost operate modific\u0103ri referitor la FORMA FARMACEUTIC\u0102, fiind acceptate &#8211; <strong>cartu\u0219\/stilou injector preumplut<\/strong> ce au permis participarea \u00een cadrul licita\u021biei publice nr. 18\/03958 a urm\u0103toarelor medicamente autorizate \u00een Nomenclatorul de Stat al Medicamentelor din Republica Moldova, dup\u0103 cum urmeaz\u0103:<\/span><\/p>\n<ul>\n<li><span style=\"color: #000000;\"><em style=\"color: #000000;\">Lantus\u00ae SoloStar\u00ae,<\/em> <em><span style=\"color: #000000;\">solutie injectabila \u00een\u00a0stilou injector preumplut, prod.: Sanofi-Aventis Deutschland GmbH, Germania<\/span><\/em><\/span><\/li>\n<li><span style=\"color: #000000;\"><em><span style=\"color: #000000;\">Lantus\u00ae 100 U\/ml, solu\u021bie injectabil\u0103 \u00een\u00a0cartu\u0219, prod.: Sanofi-Aventis Deutschland GmbH, Germania<\/span><\/em><\/span><\/li>\n<li><span style=\"color: #000000;\"><em>Strim, solu\u021bie injectabil\u0103, prod.: Farmak SAP, Ucraina.<\/em><\/span><\/li>\n<\/ul>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0P\u00e2n\u0103 la termenul limit\u0103 de depunere a ofertelor \u00a0(30.11.2018 ora 14:00), <\/strong>pentru pozi\u021bia Insulinum glarginum cu DOZA &#8211; 100 UI\/ml 3 ml <strong><em><u>au fost prezentate 4 oferte dup\u0103 cum urmeaz\u0103:<\/u><\/em><\/strong><\/span><\/p>\n<p><a href=\"https:\/\/capcs.md\/wp-content\/uploads\/2019\/07\/comunicat.jpg\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-5514\" src=\"https:\/\/capcs.md\/wp-content\/uploads\/2019\/07\/comunicat-300x105.jpg\" alt=\"comunicat\" width=\"300\" height=\"105\" srcset=\"https:\/\/capcs.md\/wp-content\/uploads\/2019\/07\/comunicat-300x105.jpg 300w, https:\/\/capcs.md\/wp-content\/uploads\/2019\/07\/comunicat.jpg 648w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>\u00a0<\/a><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Evaluarea a avut loc per pozi\u021bie, conform criteriului &#8211; la cel mai mic pre\u021b f\u0103r\u0103 TVA, cu corespunderea tuturor cerin\u021belor \u0219i a fost desemnat\u0103 c\u00e2\u0219tig\u0103toare oferta operatorului economic FPC Esculap-Farm SRL care a ofertat un produs autorizat conform Nomenclatorului de Stat al Medicamentelor din Republica Moldova \u0219i la un pre\u021b mai mic cu 39,10% comparativ cu pre\u021bul contractat pentru anul precedent pentru pozi\u021bia Insulinum glarginum.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Totodat\u0103, preciz\u0103m c\u0103 pe tot parcursul procedurii de achizi\u021bie (\u00een perioada depunerii ofertelor 28.09.2018-30.11.2018, perioada evalu\u0103rii ofertelor \u0219i semn\u0103rii contractelor de achizi\u021bii publice 30.11.2018-30.01.2018 &#8211; adic\u0103 efectiv 4 luni) nu a fost depus\u0103 nicio contesta\u021bie. Aceasta fiind desf\u0103\u0219urat\u0103 \u00een strict\u0103 conformitate cu prevederile legisla\u021biei \u00een vigoare, fiind verificat\u0103 \u0219i aprobat\u0103 de c\u0103tre Institu\u021biile abilitate \u00een domeniu.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Nota Bene:<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Centrul pentru achizi\u021bii publice centralizate \u00een s\u0103n\u0103tate este o autoritate central\u0103 pentru achizi\u021bii, subordonat\u0103 Ministerul S\u0103n\u0103t\u0103\u021bii, Muncii \u0219i Protec\u021biei Sociale, care planific\u0103 \u0219i desf\u0103\u0219oar\u0103 procedurile de achizi\u021bii publice \u00een domeniul de s\u0103n\u0103tate la ini\u021biativa Ministerului S\u0103n\u0103t\u0103\u021bii, Muncii \u0219i Protec\u021biei Sociale (MSMPS) sau a institu\u021biilor medico \u2013 sanitare publice.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Pentru cei care doresc s\u0103 se informeze din prima surs\u0103, recomand\u0103m s\u0103 acceseze site-ul institu\u021biei <span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/capcs.md\/\">https:\/\/capcs.md<\/a><\/span>.\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Comunicat de pres\u0103 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Centrul pentru Achizi\u021bii Publice Centralizate \u00een S\u0103n\u0103tate a desf\u0103\u0219urat procedura de achizi\u021bie public\u0103 privind \u201dAchizi\u021bionarea analogilor de insulin\u0103 \u0219i a preparatului Desmopressinum \u00een scopul realiz\u0103rii Programului Na\u021bional de profilaxie \u0219i combaterea diabetului&#8230; <a href=\"https:\/\/capcs.md\/en\/comunicat-de-presa\/\" class=\"read-more\">Detalii<\/a><\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-5513","post","type-post","status-publish","format-standard","hentry","category-slider"],"translation":{"provider":"WPGlobus","version":"2.10.10","language":"en","enabled_languages":["ro","ru","en"],"languages":{"ro":{"title":true,"content":true,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/posts\/5513"}],"collection":[{"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/comments?post=5513"}],"version-history":[{"count":5,"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/posts\/5513\/revisions"}],"predecessor-version":[{"id":5548,"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/posts\/5513\/revisions\/5548"}],"wp:attachment":[{"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/media?parent=5513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/categories?post=5513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/capcs.md\/en\/wp-json\/wp\/v2\/tags?post=5513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}